Citadel Advisors’s PharMerica Corporation PMC Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2017
Q4 | – | Sell |
-11,357
| Closed | -$333K | – | 8788 |
|
|
2017
Q3 | $333K | Sell |
11,357
-250,780
| -96% | -$7.02M | ﹤0.01% | 5902 |
|
|
2017
Q2 | $6.88M | Sell |
262,137
-75,991
| -22% | -$1.87M | 0.01% | 1787 |
|
|
2017
Q1 | $7.91M | Buy |
338,128
+149,142
| +79% | +$3.68M | 0.01% | 1613 |
|
|
2016
Q4 | $4.75M | Buy |
188,986
+39,613
| +27% | +$1M | ﹤0.01% | 2060 |
|
|
2016
Q3 | $4.19M | Buy |
+149,373
| New | +$3.83M | ﹤0.01% | 2158 |
|
|
2016
Q1 | – | Sell |
-39,017
| Closed | -$1.37M | – | 8769 |
|
|
2015
Q4 | $1.37M | Buy |
+39,017
| New | +$1.22M | ﹤0.01% | 3207 |
|
|
2015
Q2 | – | Sell |
-62,431
| Closed | -$1.76M | – | 9328 |
|
|
2015
Q1 | $1.76M | Sell |
62,431
-106,427
| -63% | -$2.65M | ﹤0.01% | 3230 |
|
|
2014
Q4 | $3.5M | Buy |
168,858
+125,551
| +290% | +$2.98M | ﹤0.01% | 2321 |
|
|
2014
Q3 | $1.06M | Buy |
43,307
+32,031
| +284% | +$849K | ﹤0.01% | 3641 |
|
|
2014
Q2 | $322K | Buy |
+11,276
| New | +$314K | ﹤0.01% | 4983 |
|
|
2014
Q1 | – | Sell |
-39,990
| Closed | -$860K | – | 8148 |
|
|
2013
Q4 | $860K | Buy |
39,990
+1,905
| +5% | +$34.6K | ﹤0.01% | 3369 |
|
|
2013
Q3 | $505K | Buy |
+38,085
| New | +$513K | ﹤0.01% | 3811 |
|
Citadel Advisors's PMC Position: Q4 2017 in Review
Citadel Advisors sold out of PharMerica Corporation (PMC) in Q4 2017, closing a stake of 11,357 shares — an estimated $333K sold.
Citadel Advisors first reported a position in PMC in Q3 2013 and held it in 12 quarters. The position peaked at $7.91M in Q1 2017. 0 funds tracked by Wall St. Rank hold PMC as of Q4 2017.
- Citadel Advisors reported no remaining PharMerica Corporation position as of Q4 2017 after selling out during the quarter.
- Citadel Advisors sold 11,357 PharMerica Corporation shares in Q4 2017, an estimated $333K.
- Citadel Advisors first reported a position in PharMerica Corporation in Q3 2013 and held it in 12 quarters.
- Citadel Advisors's PharMerica Corporation position peaked at $7.91M in Q1 2017.
- 0 funds tracked by Wall St. Rank held PharMerica Corporation as of Q4 2017.
Based on Citadel Advisors's 13F filing for Q4 2017, filed 9 Feb 2018.